Drugs / Copper Cu 64-DOTA-A2DM
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07608627 | Dec 2026 → Jul 2028 expected | pancreatic adenocarcinoma | City of Hope Medical Center | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Copper Cu 64-DOTA-A2DM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07608627 ↗ |
| Modality | Diagnostic / imaging agent | “for the imaging of patients with PSCA-expressing pancreatic cancer” NCT07608627 ↗ |
| Route | Intravenous | “Given 64Cu-DOTA-A2DM IV” NCT07608627 ↗ |
| Target | PSCA | “prostate stem cell antigen (PSCA) imaging using 64Cu-DOTA-A2DM” NCT07608627 ↗ |